Whalen Wealth Management Inc. Acquires Shares of 16,741 Amneal Pharmaceuticals, Inc. $AMRX

Whalen Wealth Management Inc. acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 16,741 shares of the company’s stock, valued at approximately $135,000.

Several other large investors have also bought and sold shares of AMRX. Nuveen LLC bought a new position in Amneal Pharmaceuticals during the 1st quarter valued at $19,581,000. Woodline Partners LP raised its stake in shares of Amneal Pharmaceuticals by 165.2% during the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company’s stock worth $12,604,000 after purchasing an additional 937,035 shares during the period. Vanguard Group Inc. raised its stake in shares of Amneal Pharmaceuticals by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock worth $132,092,000 after purchasing an additional 920,758 shares during the period. Acadian Asset Management LLC raised its stake in shares of Amneal Pharmaceuticals by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock worth $21,759,000 after purchasing an additional 880,471 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth $5,733,000. 31.82% of the stock is currently owned by institutional investors.

Insider Transactions at Amneal Pharmaceuticals

In related news, EVP Andrew S. Boyer sold 279,244 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the sale, the executive vice president owned 152,426 shares of the company’s stock, valued at approximately $1,429,755.88. This trade represents a 64.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the sale, the executive vice president directly owned 10,606 shares of the company’s stock, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 609,206 shares of company stock worth $5,700,625. Insiders own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AMRX. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their target price on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $10.43 on Thursday. The business has a 50-day moving average of $9.92 and a 200 day moving average of $8.60. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $10.68. The firm has a market cap of $3.28 billion, a P/E ratio of 1,044.04 and a beta of 1.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Monday, July 21st. The company reported $0.21 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%.The company had revenue of $695.42 million during the quarter. Amneal Pharmaceuticals has set its Q2 2025 guidance at EPS. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.